O'Donnell B P, Dawson N A, Weiss R B, Myers C E, James W D
Dermatology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001.
Arch Dermatol. 1992 Jan;128(1):75-9.
Suramin sodium, a polysulfonated naphthylurea, has been used for more than 70 years as a chemotherapeutic agent for a variety of diseases. In a phase II trial of suramin, 20 patients with metastatic prostate carcinoma refractory to hormonal manipulation were evaluated retrospectively for evidence of skin toxicity.
Three types of skin reaction were noted: generalized, erythematous, maculopapular eruption (10 patients); keratoacanthoma (two patients); and disseminated superficial actinic porokeratosis (one patient). A total of 15 episodes of some form of skin reaction occurred in 13 patients. The maculopapular eruptions resolved in 3 to 5 days despite continued treatment with suramin.
Cutaneous toxicity was a frequent and, often, self-limited side effect of suramin therapy, occurring in 13 (65%) patients. Keratoacanthoma and disseminated superficial actinic porokeratosis have not previously been reported to occur with suramin therapy. The immunosuppressive effect of suramin may induce the keratoacanthoma and disseminated superficial actinic porokeratosis lesions.
苏拉明钠是一种多磺酸萘脲，作为一种治疗多种疾病的化疗药物已使用了70多年。在一项苏拉明的II期试验中，对20例激素治疗无效的转移性前列腺癌患者进行回顾性评估，以寻找皮肤毒性的证据。
观察到三种皮肤反应类型：全身性红斑丘疹疹（10例患者）；角化棘皮瘤（2例患者）；播散性浅表性光化性汗孔角化病（1例患者）。13例患者共出现15次某种形式的皮肤反应。尽管继续使用苏拉明治疗，斑丘疹在3至5天内消退。
皮肤毒性是苏拉明治疗常见且通常为自限性的副作用，13例（65%）患者出现该情况。角化棘皮瘤和播散性浅表性光化性汗孔角化病此前未被报道与苏拉明治疗相关。苏拉明的免疫抑制作用可能诱发角化棘皮瘤和播散性浅表性光化性汗孔角化病损害。
